ATL3

Atlastin-3 · Q6DD88 · ATL3 on Sugi Atlas →

0 patent compounds predicted against ATL3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ATL3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL PHASE1/PHASE2RECRUITING
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1 nanCOMPLETED
Core Stability Exercises and Hereditary Ataxia nanCOMPLETED
Functional Outcome After Surgery for Cervical Disc Prolapse nanNOT_YET_RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI nanRECRUITING
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Structural Chromosome Rearrangements and Brain Disorders nanENROLLING_BY_INVITATION
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. nanCOMPLETED
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Spastic Paraplegia - Centers of Excellence Research Network nanRECRUITING
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies nanCOMPLETED
Eating Behaviour in Crohn's Disease nanCOMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
Advancing Neurogenetic Diagnoses Through Long-Read Sequencing nanNOT_YET_RECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Issues Surrounding Prenatal Genetic Testing for Achondroplasia nanCOMPLETED
Chordoma Family Study nanCOMPLETED
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program nanCOMPLETED
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ATL3 binder may also engage these)

ProteinNameSimilarity
Q0ZHH6 1.000 Q0ZHH6 →
Q91YH5 1.000 Q91YH5 →
Q8NHH9 1.000 Q8NHH9 →
Q6GN29 0.997 Q6GN29 →
Q8BH66 0.994 Q8BH66 →
Q6PA06 0.994 Q6PA06 →
Q6PST4 0.993 Q6PST4 →
Q58D72 0.990 Q58D72 →
Q8WXF7 0.988 Q8WXF7 →
Q95LN3 0.988 Q95LN3 →
Q60HD2 0.987 Q60HD2 →
Q5R4P1 0.986 Q5R4P1 →
Q9VC57 0.984 Q9VC57 →
Q8IYB8 0.979 Q8IYB8 →
Q8N1G2 0.978 Q8N1G2 →
Q04499 0.978 Q04499 →
Q5EBA1 0.977 Q5EBA1 →
Q9ER88 0.976 Q9ER88 →
Q9DBC3 0.976 Q9DBC3 →
Q5R981 0.975 Q5R981 →
F1ND48 0.975 F1ND48 →
Q925B3 0.974 Q925B3 →
F1MF74 0.974 F1MF74 →
Q6NTR1 0.973 Q6NTR1 →
Q9CQ26 0.972 Q9CQ26 →
Q5ZJT0 0.972 Q5ZJT0 →
Q6NX27 0.972 Q6NX27 →
Q80YD1 0.971 Q80YD1 →
Q28FT4 0.971 Q28FT4 →
Q5R5N9 0.971 Q5R5N9 →